INDP:NSD-Indaptus Therapeutics Inc (USD)

COMMON STOCK | Biotechnology |

Last Closing

USD 2.12

Change

0.00 (0.00)%

Market Cap

USD 0.02B

Volume

0.02M

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-06-29 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap
VRTX Vertex Pharmaceuticals Inc

+2.53 (+0.54%)

USD 120.95B
REGN Regeneron Pharmaceuticals Inc

+5.99 (+0.57%)

USD 115.81B
MRNA Moderna Inc

-2.80 (-2.36%)

USD 45.51B
ALNY Alnylam Pharmaceuticals Inc

+0.32 (+0.13%)

USD 28.20B
ARGX argenx NV ADR

+4.18 (+0.97%)

USD 26.78B
BNTX BioNTech SE

-1.53 (-1.90%)

USD 20.40B
GMAB Genmab AS

-0.28 (-1.11%)

USD 16.65B
BMRN Biomarin Pharmaceutical Inc

-0.20 (-0.24%)

USD 15.98B
RPRX Royalty Pharma Plc

-0.18 (-0.68%)

USD 15.75B
BGNE BeiGene Ltd

+2.22 (+1.56%)

USD 15.73B

ETFs Containing INDP

INDL Direxion Daily MSCI India.. 52.66 % 1.01 %

+1.03 (+0.07%)

USD 0.11B
DWCR 10.89 % 0.79 %

N/A

N/A
3010:HK iShares MSCI AC Asia ex J.. 4.18 % 0.00 %

N/A

USD 3.40B
ERTH Invesco MSCI Sustainable .. 3.11 % 0.00 %

+0.09 (+0.07%)

USD 0.18B
DMCY Democracy International F.. 2.85 % 0.00 %

+0.02 (+0.07%)

USD 7.72M

Market Performance

  Market Performance vs. Industry/Classification (Biotechnology) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 20.45% 78% C+ 84% B
Dividend Return N/A N/A N/A N/A N/A
Total Return 20.45% 78% C+ 83% B
Trailing 12 Months  
Capital Gain 10.99% 74% C 71% C-
Dividend Return N/A N/A N/A N/A N/A
Total Return 10.99% 73% C 68% D+
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain -13.84% 42% F 24% F
Dividend Return -13.84% 42% F 23% F
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 34.22% 77% C+ 55% F
Risk Adjusted Return -40.43% 36% F 23% F
Market Capitalization 0.02B 23% F 18% F

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Low market capitalization

This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector